We are live on
!
Find out more
Atossa Therapeutics
ATOS
ATOS
45 hedge funds and large institutions have $11.9M invested in Atossa Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,117% more call options, than puts
Call options by funds: $779K | Put options by funds: $64K
25% more capital invested
Capital invested by funds: $9.49M → $11.9M (+$2.36M)
0.08% less ownership
Funds ownership: 0.94% → 0.86% (-0.08%)
12% less funds holding
Funds holding: 51 → 45 (-6)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Holders
45
Holders Change
-6
Holders Change %
-11.76%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
17
Closed
8
Calls
$779K
Puts
$64K
Net Calls
+$715K
Net Calls Change
-$78K
Top Buyers
Top Sellers
| 1 |
D.E. Shaw & Co
New York
|
-$484K |
| 2 |
BlackRock
New York
|
-$191K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$105K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$103K |
| 5 |
Millennium Management
New York
|
-$74.1K |
